Literature DB >> 8307158

Distribution and characterization of immunoreactive adrenomedullin in human tissue and plasma.

Y Ichiki1, K Kitamura, K Kangawa, M Kawamoto, H Matsuo, T Eto.   

Abstract

A specific and sensitive radioimmunoassay for human adrenomedullin has been developed and distribution and characterization of immunoreactive adrenomedullin in human tissue were investigated. The radioimmunoassay specifically recognizes its carboxyterminal region and half maximal inhibition of binding of radioiodinated adrenomedullin(40-52)NH2 was observed at 11 fmol/tube. Immunoreactive adrenomedullin was abundant in adrenal medulla (47.7 +/- 26.1 fmol/mg, mean +/- S.D.) and was ubiquitously found in all tissue examined. The mean plasma concentration of adrenomedullin in three normal individuals was 17.2 +/- 6.4 pg/ml (mean +/- S.D.). By analysis with reverse-phase high-performance liquid chromatography coupled with the radioimmunoassay, most immunoreactive adrenomedullin in the adrenal medulla, atrium and lung was found to be adrenomedullin(1-52)NH2.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8307158     DOI: 10.1016/0014-5793(94)80106-1

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  39 in total

1.  Effect of Valsartan on Cerebellar Adrenomedullin System Dysregulation During Hypertension.

Authors:  Leticia Figueira; Anita Israel
Journal:  Cerebellum       Date:  2017-02       Impact factor: 3.847

2.  Rat-2 fibroblasts express specific adrenomedullin receptors, but not calcitonin-gene-related-peptide receptors, which mediate increased intracellular cAMP and inhibit mitogen-activated protein kinase activity.

Authors:  H A Coppock; A A Owji; C Austin; P D Upton; M L Jackson; J V Gardiner; M A Ghatei; S R Bloom; D M Smith
Journal:  Biochem J       Date:  1999-02-15       Impact factor: 3.857

3.  Prognostic value of plasma MR-proADM vs NT-proBNP for heart failure in people with type 2 diabetes: the SURDIAGENE prospective study.

Authors:  Mathilde Fraty; Gilberto Velho; Elise Gand; Fréderic Fumeron; Stéphanie Ragot; Philippe Sosner; Kamel Mohammedi; Barnabas Gellen; Pierre-Jean Saulnier; Jean-Michel Halimi; David Montaigne; Grégory Ducrocq; Michaela Rehman; Michel Marre; Ronan Roussel; Samy Hadjadj
Journal:  Diabetologia       Date:  2018-09-19       Impact factor: 10.122

4.  Pregnancy Increases Relaxation in Human Omental Arteries to the CGRP Family of Peptides.

Authors:  Yuanlin Dong; Ancizar Betancourt; Madhu Chauhan; Meena Balakrishnan; Fernando Lugo; Matthew L Anderson; Jimmy Espinoza; Karin Fox; Michael Belfort; Chandrasekhar Yallampalli
Journal:  Biol Reprod       Date:  2015-10-28       Impact factor: 4.285

Review 5.  Novel neurohumoral factors in congestive heart failure: adrenomedullin.

Authors:  J G Lainchbury
Journal:  Curr Cardiol Rep       Date:  2001-05       Impact factor: 2.931

6.  Plasma adrenomedullin as an indicator of prognosis after acute myocardial infarction.

Authors:  N Nagaya; T Nishikimi; M Uematsu; Y Yoshitomi; Y Miyao; S Miyazaki; Y Goto; S Kojima; M Kuramochi; H Matsuo; K Kangawa; H Nonogi
Journal:  Heart       Date:  1999-05       Impact factor: 5.994

7.  Immunohistochemical identification of adrenomedullin in human, rat, and porcine tissue.

Authors:  H Washimine; Y Asada; K Kitamura; Y Ichiki; S Hara; Y Yamamoto; K Kangawa; A Sumiyoshi; T Eto
Journal:  Histochem Cell Biol       Date:  1995-04       Impact factor: 4.304

8.  Treating pulmonary arterial hypertension: current treatments and future prospects.

Authors:  Shahzad G Raja; Shahbaz M Raja
Journal:  Ther Adv Chronic Dis       Date:  2011-11       Impact factor: 5.091

Review 9.  Adrenomedullin and diabetes.

Authors:  Hoi Kin Wong; Fai Tang; Tsang Tommy Cheung; Bernard Man Yung Cheung
Journal:  World J Diabetes       Date:  2014-06-15

10.  Adrenomedullin in cirrhotic and non-cirrhotic portal hypertension.

Authors:  V Tahan; E Avsar; C Karaca; E Uslu; F Eren; S Aydin; H Uzun; H O Hamzaoglu; F Besisik; C Kalayci; A Okten; N Tozun
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.